Press
NonWoTecc Medical GmbH successfully completes second financing round of €7 million
Cologne-based medical technology company NonWoTecc Medical GmbH is receiving growth financing from NRW.BANK as well as from an industry-experienced consortium of private investors headed by Rainer Christine. Previous investors Rheinland Venture Capital, Kreissparkasse Köln, High-Tech Gründerfonds and KfW are also participating in the second financing round.
The fresh capital of €7 m is to be used for the product approval and launch of vascular prostheses in the peripheral and coronary areas
Press
GeneQuine Biotherapeutics Secures more than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases
Proceeds will facilitate development of GeneQuine’s gene therapy pipeline for musculoskeletal disorders and vector platformLead gene therapy candidate GQ-303, a potentially disease-modifying treatment for osteoarthritis, will be advanced to Phase 1 clinical trialGene therapy program for intervertebral disc degeneration will be acceleratedCompany is expanding with additional site and staff
GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for mu
Press
Neural Concept raises a $9.1m Series A to scale Engineering Intelligence within industrial organizations
Neural Concept raises a $9.1m Series A, led by AlvenThis additional capital will help foster the adoption of Engineering Intelligence to accelerate product development in the Automotive and Aerospace industries.Today, Neural Concept’s Deep-Learning based software is used by more than 25 industrial companies and engineering teams.
Lausanne, March 22nd 2022 – Neural Concept, the Engineering Intelligence company, has raised a $9.1 m Series A, led by Alven with the participation o
Press
evocatal GmbH Closes New Financing Round
evocatal GmbH, based in the Life Science Center Düsseldorf, has closed € 2 million in growth financing. Thus the industrial biotech company puts itself in a position to continue successfully started projects rigorously to market readiness.
The current financing round is chaired by new investor Roland Oetker, who, together with existing investors High-Tech Gründerfonds (HTGF), Sirius Seedfonds Düsseldorf (SSFD) and business angel Prof. Riesner, provides € 2 million in growth capital. Fo
Press
medineering GmbH, a Munich based medtech company, closes seed investment round
Innovative robotic products for the minimally invasive surgery
medineering GmbH successfully closed its first investment round in August 2014. The High-Tech Gründerfonds (HTGF), Bayern Kapital, Born2Grow as well as a consortium of business angels will be supporting the Munich medtech company in the future. The investors were intrigued by medineering's product portfolio and its potential to optimize the workflow within operating theatres. The investment will now be used for developing and r
Press
Strategic investment for baimos technologies by automotive supplier company
Automotive supplier Marquardt, High-Tech Gründerfonds and Bayern Kapital strengthen their ties with baimos technologies, a leader in the field of mobile security solutions.
BlueID technology, a system for secure digital identification by mobile phone, meets growing interest in the automotive sector. BlueID Drive is a development of baimos technologies and automotive supplier Marquardt. It provides the possibility to send access permissions and driver authorizations to mobile phones. In turn, c
Press
Fresh capital for innovative allergy prevention
Protectimmun GmbH has successfully closed a first financing round totalling EUR 1.3 Million.
High-Tech Gründerfonds (HTGF), ELS-Fonds managed by EnjoyVenture, and KfW invest in the innovative approach for protection against the development of hay fever and allergic asthma together with a private investor and the team of founders.
"We are very pleased to get these experienced partners on board, says Dr. Marion Kauth, CEO and co-founder of Protectimmun. "This financing enables us to rapidly
Press
Bayer and Boehringer Ingelheim invest in HTGF III
Bayer and Boehringer Ingelheim’s investment fund BIVF (Boehringer Ingelheim Venture Fund) are investing in High-Tech Gründerfonds’ third fund, HTGF III. The investment grants the two international pharmaceutical companies access to innovative life science start-ups along with the fund’s large-scale network spanning the entire start-up landscape. High-Tech Gründerfonds, Europe’s most active seed investor, launched its third fund back in September 2017. HTGF III has a final target volume
Press
Third round financing for GILUPI GmbH with Aurelia Private Equity, Brandenburg Capital (BFBII), KfW Bankengruppe and High-Tech Gründerfonds
GILUPI GmbH is an innovative company developing and producing medical devices for the in vivo isolation of rare cells out of the circulating blood. GILUPI will use the current financing mainly for the CE-certification and the subsequent introduction into the market of its patented medical detector.
The early approval of the device according to the MPG (Medical Devices Act) is essential for achieving the economic objectives of GILUPI. New innovative products for isolating rare cells out of the
Jessica Lingenfelder – Head of People & Culture
As a Head of P&C, Jessica Lingenfelder is responsible for a wide range of personnel matters around the entire HTGF-team. This includes recruiting, employer branding and strategic personnel marketing as well as employee development, retention management but also human resources and team culture.
Before she undertook this task in 2018, she was as a Human Resources Manager among other things responsible for the development and the advancement for the recruiting at a medium-sized it-provider. Jessica is a qualified coach and moderator. After her university degree from the university of Bielfeld, she spent seven years working in human resources consulting before changing to the cooperate side.
Press
coramaze technologies raises EUR 4.5 million to advance novel transfemoral mitral valve repair system into the clinic
mitramaze® – First transfemoral mitral valve repair system with atraumatic anchoring being developed
coramaze technologies GmbH, a German medical device company, is developing the mitramaze® valve repair system – a novel concept for transcatheter mitral valve repair (TMVRep) intended for treatment of inoperable patients suffering from severe functional mitral regurgitation (fMR). coramaze announced today the closing of a EUR 4.5 million (US$ 5.15 million) series A financing round led by
Portfolio
payever (Exit)
payever was founded to make commerce easier for businesses of all types and sizes. The company provides a modular SaaS solution to sell everywhere and accept all payments.
Portfolio
Bind-X
https://www.linkedin.com/company/bind-x
Frank Kerim Reinecke – Partner – Digital Tech
Since June 2019, Frank has been building up his software portfolio at High-Tech Gründerfonds. Before that, he founded and sold three of his own start-ups. Subsequently, he initiated and was responsible for an incubator for an international independent IT service provider (consulting). He enjoys successfully implementing innovations with start-ups. Frank studied innovation management and marketing at the Humboldt University in Berlin.
Portfolio
gestigon (Exit)
Gestures are the most natural and global form of human communication. But todays IT environment forces us to use abstract control devices, e.g. keypads, mouse, touch or – on a basic level – voice control. By introducing gestures to the human-machine-interface the communication becomes more intuitive, natural, faster and fun. Today, there are some proprietary 3D sensors in the market with linked software solutions but there is a lack of a stable, reliable as well as resource efficient middlew
Portfolio
MAGAZINO (Exit)
MAGAZINO develops, builds and sells innovative storage and picking machines. They enable highly efficient individual item storage and dispensing of a wide range of objects.
Exit since May 2015. Purchaser: Siemens Novel Businesses.